Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

NCT03240861 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped slow accrual

Conditions

HLA-A*0201 Positive Cells Present
Locally Advanced Malignant Neoplasm
NY-ESO-1 Positive
Unresectable Malignant Neoplasm
Sarcoma

Interventions

OTHER: 18F-FHBG
BIOLOGICAL: Aldesleukin
DRUG: Busulfan
BIOLOGICAL: Cellular Therapy
PROCEDURE: Computed Tomography
BIOLOGICAL: Filgrastim
DRUG: Fludarabine
PROCEDURE: Leukapheresis
DRUG: Plerixafor
PROCEDURE: Positron Emission Tomography

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]